River Road Asset Management LLC Has $7.21 Million Position in Amgen Inc. $AMGN

River Road Asset Management LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 40.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,044 shares of the medical research company’s stock after selling 15,112 shares during the quarter. River Road Asset Management LLC’s holdings in Amgen were worth $7,215,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. increased its position in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in shares of Amgen during the fourth quarter worth $1,669,000. Adell Harriman & Carpenter Inc. lifted its holdings in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Amgen in the fourth quarter worth $22,441,000. Finally, Sigma Planning Corp grew its stake in shares of Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after purchasing an additional 3,488 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $337.60 on Friday. The company has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business’s 50-day moving average is $340.71 and its 200-day moving average is $345.76. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analyst Weigh In

AMGN has been the subject of several analyst reports. Wells Fargo & Company raised their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Canaccord Genuity Group initiated coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target on the stock. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Morgan Stanley raised their price objective on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 9th. Finally, Truist Financial lifted their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $354.42.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.